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Introduction
Cardiovascular disease is the major cause of death throughout the world [1] . Heart failure caused by acute myocardial infarction (AMI) is the major factor of disease caused death in the world [2] . AMI occurs most when there is a rupture of coronary artery which contains an atherosclerotic plaque, and that may cause thrombosis and occlusion of the artery, stop the blood supply in that region of heart and cause necrosis of the affected area [3] . Although cardiogenic stem cells have been proven to reside in the heart, their number is severely limited [4] . Moreover, the rate of its proliferation is slow and can rarely meet the demand for tissue regeneration after severe myocyte damage. So, stem cell transplantation [5] as well as gene therapies [6] turned to be promising strategies in the treatment of AMI since they can replenish the myocyte number and stimulate angiogenesis.
Endothelial progenitor cells (EPCs) existing in bone marrow (BM) and peripheral blood have high proliferative potential and could form neovascularization to a limited extent [7] [8] [9] . In vitro, EPCs can differentiated into endothelial lineage cells, and in animal models of ischemia, EPCs are shown to incorporate into sites of active neovascularization [10] [11] [12] . Endothelial nitric oxide synthase (eNOS) and its bioactive product nitric oxide (NO) are well-established proangiogenic molecules [13] . eNOS-derived NO regulates cardiac myocyte function, myocardial neovascularization, and myocardial perfusion. Whereas, the bioavailability of eNOS-derived NO is severely reduced in both experimental myocardial infarction and in humans with heart failure [14, 15] . Transplantation of modified cells expressing eNOS could be an attractive alternative for NO production in tissues.
In this study, we investigated our hypothesis that restoration of NO availability by transplantation of modified EPCs expressing eNOS could reduce infarction area and improve cardiac function. An important aspect of this study was to delineate the advantage of EPCs carrying eNOS as origin of NO production during cardiac repair.
Materials and Methods

Ethic statement
The study protocol was approved by the medical ethics committee of Shanghai Changhai Hospital, conforms to the Principles of Laboratory Animal Care (National Society for Medical Research), and was conducted according to National Institutes of Health guidelines.
Preparation of EPCs and cell culture
For culture of mouse EPCs, BM-mononuclear cells from C57BL/6 mouse were collected by density gradient centrifugation with Ficoll-Isopaque Plus (Histopaque-1077, Sigma) and were plated at a density of 0.8-1.0 x 10 6 cells/cm 2 on mouse plasma vitronectin-coated (Sigma-Aldrich) dishes with EC basal medium (EBM, Cambrex) supplemented with 10% fetal bovine serum (FBS, Logan, UT), 50 µg/mL ascorbic acid, 100 units/mL penicillin, and 100 µg/mL streptomycin. Incubation was carried out at 37°C in a 5% CO 2 incubator. Nonadherent cells were removed, and medium was replaced with fresh medium at day 4. The cells were maintained through day 7 and used as an EPC-enriched population.
Flow cytometric analysis
The identity of EPCs is based on the principle of flow cytometry analysis (2-parameter, single-color and 15-mW argon laser; Becton Dickinson, CA) by assessing the surface markers. FITC-conjugated anti-CD34, anti-CD45, PE-conjugated anti-CD133 and anti-KDR antibodies (Jackson IRL, Baltimore, MD) were used. CD34+/CD133+/KDR+/CD45-cells were identified as EPCs. The data were collected from 20,000 cells for each sample and analyzed with CellQuest software (Becton Dickinson, CA).
Lentivirus infection
Human eNOS cDNA was cloned by Polymerase Chain Reaction (PCR), and then eNOS cDNA was subcloned into lentiviral vectors pPRIME-CMV-GFP-FF3 carrying Green Fluorescent Protein (GFP) as reporter. The recombinant lentivirus with eNOS was produced by co-transfection of HEK293T cells with plasmids pPRIME-CMV-eNOS, lenti-eNOS-GFP virus was added to EPCs dishes when the EPCs were about 60% confluence. Viral infection was carried out at 37°C in a 5% CO 2 incubator for 12 h with the virus concentration was 10 MOIs. The empty lentiviral vector lenti-GFP was used as negative control. Three days after viral infection, EPCs were collected and examined to detect the level of eNOS by using western blot and RT-PCR.
Western blotting analysis
Radio-immunoprecipitation assay buffer (Beyotime, Shanghai, China) was used to extract protein from EPCs (or EPCs overexpressing eNOS or carrying empty lentiviral vector) or cardiac tissue. The protein expression was measured by western blot. In brief, the total protein concentration was determined by the BCA protein Assay Kit (Beyotime). Protein was separated by 8% ~ 15% sodium-dodecylsulphatepolyacrylamide gel electrophoresis (SDS-PAGE). Then, protein was transferred to nitrocellulose membranes (Amersham Bioscience, Piscataway, NJ) and incubated with the antibodies (eNOS, 1:1000 and GAPDH, 1:5000, all purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA). After that, the membrane was washed with 50 mM PBS with 0.05% Tween (PBS-T, pH 7.6) three times and incubated for 1 h at room temperature with peroxidase cojugated IgG. The level of GAPDH was analyzed in parallel as a normalized control.
Reverse transcription polymerase chain reaction (RT-PCR)
Total cellular RNAs were extracted using Trizol TM reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. RNA (0.2 μg) was reverse transcribed using the High Capacity cDNA synthesis kit (Applied Biosystem, California, USA) according to the manufacturer's instructions. Human eNOS cDNA (Accession: NM_000603) was amplified using primers 5'-CTT TGC TCG TGC CGT GGA CA-3' and 5'-GCC CTC GTG GAC TTG CTG CT-3'. Mouse GAPDH cDNA served as housekeeping gene (Accession: NM_008084) and was amplified in parallel with the target gene using primers 5'-ATT GTC AGC AAT GCA TCC TG-3' and 5'-ATG GAC TGT GGT CAT GAG CC-3'. PCR °C was done at the end. Products were analyzed on 1.5% agarose gel.
AMI models preparation and cell transplantation
The EPCs were digested with trypsase, followed by centrifugation at 37°C 3000 rpm for 15min. The supernatant was removed, and FBS-free medium was added into the cell pellet. Then the cell suspension was filtered with a 25-µm sieve to eliminate the clumped cells. Before injection, the EPCs suspension was examined under a microscope to ensure no evident cell mass in the suspension.
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Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry 6-10-weeks-old C57BL/6 mice were provided by Shanghai Changhai Hospital and underwent myocardial ischemia by occluding the left coronary artery as described previously [16] . Briefly, mice were anesthetized with an intraperitoneal injection of avertin (0.014 mg/kg; 2, 2, 2-Tribromoethanol; Sigma), the chest was opened and the ribs were gently spread. Ligation of the left anterior descending artery (LAD) was performed 1 to 2 mm distal to the line between the left border of the pulmonary conus and the right border of left atrial appendage, and then the heart was repositioned to the chest. Animals were assessed by echocardiography to make sure that acute myocardial infarction (AMI) models were prepared successfully. Experimental animals were randomized for sham operated group (sham, n = 15), medium control group (medium, n = 15), eNOS lentiviral vector injection group (lenti-eNOS, n = 15), control EPCs transplant group (EPCs, n = 15), and eNOS-EPCs transplant group (eNOS-EPCs, n = 15). The transplantation was performed at 1 h after induction of AMI. Multiple intramyocardial injections of 20 µl basal medium or eNOS lentiviral vector without cells, or cell suspension containing 1x10 5 EPCs (or eNOS-EPCs) were carried out in the free wall of the left ventricle (LV).
Enzyme-linked immunosorbent assay (ELISA) analysis
At the day 3 after transplantation (additional experiment, n=5 of each group), mice were humanely sacrificed and the hearts were removed. The ELISA kit (R&D System, Minneapolis, MN, USA) was used for determination of pro-inflammatory cytokines TNF-α and IL-1β levels in cardiac protein according to manufacturer instruction. Tissues from infarcted area of transplant groups or anterior left ventricular of sham operated group were homogenized in ice-cold PBS buffer containing protease inhibitor cocktail (21 mmol/L leupeptin and 3.1 nmol/L aprotinin), and total proteins were extracted using a protein extraction kit (Pierce, Rockford, IL, USA). Total protein concentration was determined using a protein assay kit (Pierce, Rockford, IL, USA).
Echocardiography
All mice were anaesthetized by intraperitoneal injection with ketamine (5 mg/100 g). Transthoracic echocardiography was performed using a Vevo770 imaging system (VisualSonics Inc., Toronto, Ontario, Canada) with a 30-MHz probe. We measured the left ventricular (LV) end-diastolic and end-systolic areas at two-dimensional mode and the LV end-diastolic diameter (LVEDD) and LV end-systolic diameters (LVESD) at one-dimensional mode, as described previously [17] . LV fractional shortening (FS) was calculated following formula: FS (%) = (LVEDD -LVESD)/LVEDD×100. The investigator performing and reading the echocardiogram was blinded to the treatment allocation.
Hemodynamic measurements
All mice were anaesthetized by intraperitoneal injection with ketamine (8 mg/100 g). The LV apex was punctured and a Millar catheter connected to a pressure transducer was inserted. The aortic blood pressure (BP), LV systolic pressure (LVSP), LV end-diastolic pressure (LVEDP) and the maximal rates of rise and fall in LV pressure (+dP/dt, -dP/dt) were recorded [17] . The measurements were made from consecutive 15 beats and averaged.
Histological analysis
After the 28-day echocardiographic and hemodynamic measurements, all mice were humanely sacrificed. Hearts were cut into three transverse segments, fixed in 10% formaldehyde and embedded in paraffin. Section were cut at 10-µm from each segment, and stained with hematoxylin and eosin (H&E). Then 3-4 sections from each heart were scanned on both surfaces using a digital flatbed scanner. The infarcted size was measured digitally using Image Pro Plus software (Media Cybernetics). The infarct size was presented as percentage of the LV.
To quantify the vessel density in the per-infarct area, other sections were incubated with 0.6% H 2 O 2 , and permeabilized with 0.2% Triton X-100 for 5 min. After blocking with 1% fish gelatin (Sigma) for 1 hour at room temperature, the sections were incubated with a rabbit anti-mouse monoclonal factor VIII antibody (1:2000; Zymed, San Francisco, CA, USA) overnight at 4°C, then washed with PBS three times, and incubated with goat anti-rabbit IgG (1:500; Santa Cruz, CA, USA). The sections were colored with streptABComplex/ horseradish peroxidase Duet kit (Dako Ltd., Cambridge, UK) and counterstained with hematoxylin. Vessels 
NO measurements
The amount of NO in cardiac tissue was determined using an NO assay kit (Beyotime, Shanghai, China) according to the manufacturer's protocol. Briefly, tissue samples from the risk area were rinsed, homogenized in deionized water (1:10, wt/vol), and centrifuged at 14 000 g for 10 minutes. The absorbance was measured with a microplate reader (BioRad, Hercules, CA, USA) at 550 nm after enzymatic conversion of the supernatant nitrate to nitrite by nitrate reductase, and supernatant NO levels were determined by colorimetric assay.
Statistical analysis
All data were presented in means ± standard deviations (SD). Statistical comparisons between two groups were done using the t-test and among multiple groups by ANOVA. The level of significance was determined through value of P<0.05.
Results
Properties of EPCs
EPCs phenotype was confirmed by the presence of double positive cells for acLDL and UEA-1 (Fig. 1A) . Flow cytometric analysis showed that EPCs were positive for their surface markers CD34, CD133 and KDR, but negative for CD45 before (Fig. 1B) and after (Fig. 1C) transfection of eNOS lentiviral vector.
Characterization of EPCs transduced with eNOS lentiviral vector
eNOS expression was forced in EPCs by transfection with lentivirus. A lentiviral vector pPRIME-CMV-GFP-FF3 carrying GFP was used. To package the lentiviral vector containing eNOS, pPRIME-CMVGFP-FF3 carrying eNOS and three helper plasmids were co-transfected into HEK293T cells; 48 h later, almost 90% cells were GFP positive ( Fig. 2A, B) . Then the packaging cell supernatant was collected, concentrated and used to infect EPCs. The empty lentivirus was used as a negative control. Forced eNOS expression was validated, as shown by western blot with an anti-eNOS antibody and RT-PCR (Fig. 2C, D) , while no eNOS overexpression was seen in cells infected with the control lentiviral vector.
Improvement of myocardial repair after infarction by transplantation of eNOS-EPCs
To evaluate the potential of eNOS-EPCs on myocardial repair, we evaluated the functional consequence of transplantation of eNOS-EPCs mouse AMI model in vivo. After induction of myocardial infarction by permanent occluding the left anterior descending coronary artery (Table 1) , medium, eNOS lentiviral vector, EPCs, and eNOS-EPCs were implanted into the infarcted area.
At the day 3 after transplantation, the levels of TNF-α and IL-1β in the infarcted zone decreased significantly in the eNOS-EPCs group compared with the other three transplant groups (Fig. 3A and B) . However, the levels of TNF-α and IL-1β in the infarcted zone of eNOSEPCs group were remained increased significantly when compared with sham operated group. At the day 28 after AMI, mice in eNOS-EPCs transplant group exhibited a significant (p<0.05) decrease of mortality compared with sham operated group. However, transplantation of eNOS-EPCs significantly (p<0.05) increased surviving rate compared with the other transplant groups, and survival was increased by 40% in the eNOS-EPCs group compared to medium group (Fig. 4A) . Left ventricular function was measured by echocardiography and pressure-volume system at day 28 after AMI (before sacrifice). Mice displayed significant LV remodeling, including reduced LV dimensions and increased fractional shortening in the three transplant groups compared with the medium control group (Table 2) . Moreover, fractional shortening decreased from 30.1% to 22.4% in the medium control group from 1 h (Table 1 and 2), which showed that eNOS-modified EPCs transplantation administered at 1 h after induction of AMI prevented the further deterioration of cardiac function that occurred between 1 hour and 28 days following AMI. Consistently, medium control group animals showed a significant reduction of +dP/dt and -dP/dt compared with the three transplant groups. Importantly, myocardial function was significantly improved in eNOS-EPCs transplant group Table 2 . Echocardiography and hemodynamics data of all mice at day 28 after transplantation. BW, body weigh; HR, heart rate; HW, heart weigh; LV, left ventricular; LVEDD, LV end-diastolic dimension; LVESD, LV end-systolic dimension; FS, fractional shortening; MBP, mean blood pressure; LVSP, LV systolic pressure; LVEDP, LV end-diastolic pressure; +dP/dt, the maximal rates of rise in LV pressure; -dP/dt, the maximal rates of fall in LV pressure. Data are expressed as mean ± SD. *p<0. The eNOS over-expression in cardiac tissue was observed in the eNOS-EPCs and eNOS lentiviral vector groups (Fig. 3C) , and NO levels were increased significantly in the eNOSEPCs and eNOS lentiviral vector group compared to the other three groups (Fig. 3D) . In the histological analysis, H&E staining of cardiac tissue revealed that the infarct size was smallest in the group that received eNOS-EPCs transplantation (Fig. 4B) . Quantitative analyses also demonstrated that mice treated with eNOS-EPCs had significantly small myocardial infarct size compared with the medium control group (Fig. 4B) . As shown in Figure 4C , an increased number of vessels were observed in the sections of immunohistochemical staining for factor VIII in the peri-infarct region in the three transplant groups. Thus, we can speculate that mice treated with the eNOS-EPCs transplantation significantly improve the myocardial repair in the AMI model, and myocardial repair is very likely to be mediated by improving angiogenesis and reducing inflammatory factors TNF-α and IL-β.
Discussion
Improvements in heart repair and reduced infarction size in AMI mice after transplantation of eNOS-EPCs are the paramount finding of this study. It is speculated that the improvements in cardiac repair are a result of improved angiogenesis in the eNOS-EPCs mice. These findings support the idea that physiological levels of NO exert beneficial effects in the setting of acute and chronic heart infarction. Endothelial dysfunction and failed angiogenesis occurs in patients with heart infarction [18, 19] . NO has been extensively studied regarding its proangiogenic roles in endothelial homeostasis, migration, proliferation, and tube formation [20] . eNOS is present in the vascular endothelium, platelets and several other cell types that continuously produce modest amounts of NO. The loss of endothelium-derived NO could result in vascular abnormalities [20] . Therefore, a decreased expression of eNOS may contribute to the development of cardiovascular disease, including AMI. Experimental studies [21, 22] indicated that eNOSdeficient mice enhanced cardiac hypertrophy and diminished myocardial capillarization. Studies [23] [24] [25] also demonstrated that genetic deficiency of eNOS resulted in significant pulmonary hypertension and right ventricular remodeling. Furthermore, Maas R. et al. [26] found that the expression of eNOS protein in patients with AMI was markedly lower than the healthy people, an in vitro study of Kaur S et al. [27] demonstrated that eNOS-modified EPCs can improve the angiogenic properties of EPCs from patients with coronary artery disease, and studies [28, 29] also showed that elevated eNOS expression using transgenic mice with overexpression of eNOS can attenuate LV remodeling and dysfunction after AMI in mice. In the present study, mice injected with eNOS-EPCs had improved coronary vascularity compared with mice of control EPCs. These findings, in conjunction with the present results, provide significant support for a protective role of eNOS-derived NO in infarct-induced congestive heart failure.
The present data demonstrate significant beneficial effects in eNOS-EPCs transplantation during AMI. Although the mechanism of reduced infarction area appears to be related to improvement in local angiogenesis [21, 28] , the mechanism of improved angiogenesis remains unclear. One possible mechanism is that implanted EPCs with eNOS overexpression are attributing to both enhanced paracrine effect and increased endothelial cell differentiation [30] [31] [32] . The increased bioavailability of NO may attenuate the loss of capillaries that occurs during AMI and may actually potentiate the formation of new vessels [33] . Angiogenesis gene, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and erythropoietin (EPO), may be modulated by NO production in the process of angiogenesis [34] . In addition, the enhanced NO production in the eNOS-EPCs recipient hearts may protect against ventricular arrhythmia and reduce mortality after AMI [14] . The third potent mechanism of therapeutic effect by eNOS-EPCs may be that eNOS-EPCs could modulate local inflammation, which plays an important role in tissue damage of heart disease [35] . Thus, EPCs with eNOS overexpression play an important role to improve heart function in the setting of AMI. However, this study can explain only a small part of mechanism of AMI. Additional studies are required to elucidate the molecular mechanism by which eNOS is involved in AMI.
In conclusion, transplantation of the eNOS-EPCs significantly improves heart repair after severe AMI in mice. These data provided clear evidence of the beneficial role of eNOS enhanced EPCs during AMI. Further studies should be directed toward identifying the mechanism of this protective effect. In the future, therapies by transplantation of stem cell carrying exogenous gene might be developed to improve clinical outcomes in patients with AMI.
